Beigene (NASDAQ:ONC) Trading Down 7.7% – Should You Sell?

Shares of Beigene, Ltd. (NASDAQ:ONC) fell 7.7% during trading on Monday . The company traded as low as $214.12 and last traded at $220.03. 219,944 shares traded hands during mid-day trading, a decline of 52% from the average session volume of 459,486 shares. The stock had previously closed at $238.51.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on ONC shares. Macquarie increased their price objective on shares of Beigene from $259.00 to $313.00 and gave the stock an “outperform” rating in a research note on Friday, February 28th. Guggenheim reiterated a “buy” rating on shares of Beigene in a research report on Friday, February 28th. JMP Securities set a $348.00 price objective on shares of Beigene in a research note on Friday, February 28th. Royal Bank of Canada initiated coverage on Beigene in a research note on Monday. They set an “outperform” rating and a $312.00 target price for the company. Finally, Bank of America raised Beigene from a “neutral” rating to a “buy” rating and raised their target price for the company from $207.00 to $320.00 in a report on Monday, March 3rd.

Beigene Stock Performance

The company has a market capitalization of $21.76 billion, a P/E ratio of -26.76, a P/E/G ratio of 7.73 and a beta of 0.49. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. The company’s fifty day moving average is $251.40.

Beigene (NASDAQ:ONC) last posted its earnings results on Thursday, February 27th. The company reported ($1.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.55). Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The company had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.09 billion. As a group, analysts expect that Beigene, Ltd. will post -5.82 EPS for the current fiscal year.

Insider Activity

In related news, COO Xiaobin Wu sold 51,921 shares of the stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $281.40, for a total value of $14,610,569.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bros. Advisors Lp Baker sold 732,827 shares of the firm’s stock in a transaction on Friday, February 28th. The stock was sold at an average price of $260.00, for a total value of $190,535,020.00. Following the transaction, the director now directly owns 730,642 shares of the company’s stock, valued at approximately $189,966,920. This represents a 50.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,104,288 shares of company stock valued at $285,064,819. 7.43% of the stock is currently owned by corporate insiders.

About Beigene

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.